or the tone of the autonomous nervous system [9] ; the circadian rhythm; environmental factors like medication, but also neuropsychological factors like mood, stress or a depressive mental state. All these factors may impact the prognostic value of HR in HF patients.
While the authors shed an important light on this complex relation between HR and mortality, we would caution to jump from this correlation between HR at discharge and mortality to a conclusion of causality all too quickly. Of note, the current guidelines for acute and chronic HF recommend that in general, beta-blocker therapy should be initiated cautiously due to the potential of bradycardia and aggravating HF symptoms [10] . In this line, tolerability of initiation and up-titration of HF medication during the hospital stay may well influence the individual patients acute state of convalescence and thereby HR at discharge, apart from the discharge dose of negatively dromotropic medications like betablockers and ivabradine. Furthermore, ambulatory up-titration of HF medication is not only depending on the recommendations at discharge, but also on the continued dose adjustments made by office-based cardiologists and General Practitioners [11] . As the predictiveness of HR at discharge for mortality seems to be highest early after discharge from the hospital (within 30 days), it would also be interesting to see HR explored as a time-varying covariate in future studies (e.g. through continuous analysis of HR in implanted ICD). Besides, unknown confounding factors of the studied population that may have significantly contributed to the reported observations cannot be excluded. Thus, the study remains interesting and hypothesis generating but needs to be varified in a randomized trial.
In summary, while we have gained valuable insights into the complex phenomenon of HF, many questions remain open. The study shows, that discharge HR may predict one-year mortality, with higher HR portending a higher mortality risk in HF patients. However long-term outcomes were not reported. Future randomized studies are warranted to assess the (true) prognostic significance of discharge HR and to determine, whether discharge HR may be used for risk stratification and to initiate a more personalized and intense follow-up or rehabilitation program. We thank the authors for their important contribution and are looking forward to the adjustments in clinical pathways that this study may open. 
